Therapeutic advantage of 90yttrium- versus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3186-3192

  Cardillo, Thomas M ^a   Gold, David V ^a   Ying, Zhiliang ^b  

^a GARDEN STATE CANCER CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHIMERIC ANTIBODY; INDIUM 111; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PAM 4; RADIOISOTOPE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; ISOTOPE LABELING; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; MUCINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 0034800607     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cancer statistics
2. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin
3. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4
4. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer
5. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer
6. Localization of pancreatic cancer with monoclonal antibody PAM4
7. New approaches in biology, diagnosis, and treatment
8. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels
9. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells
10. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors
11. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells
12. A method of trace iodination of proteins for immunological studies
13. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies
14. Comparison of therapeutic efficacy and host toxicity of two different 1-131-labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model
15. 131I-radiolabeled Mab-PAM4 for radioimmunotherapy of experimental human pancreatic cancer
16. 131-labeled monoclonal antibody PAM4
17. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
18. 67Cu-2 IT-BAT-Lym-1 for non-Hodgkin's lymphoma
19. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy on non-Hodgkin's lymphoma
20. 90Y-labeled anti-CD20 monoclonal antibody
21. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a Phase I clinical study
22. 2 anti-carcino-embryonic antigen Mab and AHSCR
23. 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
24. y monoclonal antibody B3
25. Advantage of yttrium-90-1abeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft
26. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
27. 90Y labeled MAbs
28. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts
29. Selection of radioimmunoconjugates for the therapy of well-established or micrometastic colon carcinoma
30. Identification of the sites of IgG catabolism in the rat
31. Major digestive glands
32. Haematological effects of radioimmunotherapy in cancer patients
33. Hematological side effects of radiolabeled immunoglobulin therapy
34. Application of cytokine intervention for improved radio-antibody dose delivery
35. Myelosuppressive changes from single or repeated doses of radioantibody therapy: Effect of bone marrow transplantation, cytokines, and hematopoietic suppression
36. Model-based calculation for effective cancer radioimmunotherapy
37. Suppression of tumor vascular activity by radioantibody therapy: Implications for multiple cycle treatments
38. Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeability
39. Changes in tumor vascular permeability in response to experimental radioimmunotherapy: A comparative study of 11 xenografts
40. Radioimmunotherapy of solid tumors: A review "of mice and men
41. 131I-labeled monoclonal anti-body CC49
42. 131I-Lym-1 antibody
43. Intraperitoneal radioimmunotherapy with human monoclonal IgM in nude mice with peritoneal carcinomatosis
44. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry